Proposed issue of securities
Announcement Summary
Entity name
MESOBLAST LIMITED
Announcement Type
New announcement
Date of this announcement
Thursday August 6, 2020
The Proposed issue is:
A placement or other type of issue
Total number of +securities proposed to be issued for a placement or other type of issue
Maximum Number of | ||
ASX +security code | +Security description | +securities to be issued |
MSB | ORDINARY FULLY PAID | 212,244 |
Proposed +issue date
Thursday August 6, 2020
Refer to next page for full details of the announcement
Proposed issue of securities | 1 / 5 |
Proposed issue of securities
Part 1 - Entity and announcement details
1.1 Name of +Entity
MESOBLAST LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
1.2 | Registered Number Type | Registration Number |
ABN | 68109431870 | |
1.3 | ASX issuer code | |
MSB |
- The announcement is New announcement
- Date of this announcement
Thursday August 6, 2020
1.6 The Proposed issue is:
A placement or other type of issue
Proposed issue of securities | 2 / 5 |
Proposed issue of securities
Part 7 - Details of proposed placement or other issue
Part 7A - Conditions
7A.1 - Are any of the following approvals required for the placement or other type of issue?
+Security holder approval
Court approval
Lodgement of court order with +ASIC
ACCC approval
FIRB approval
Another approval/condition external to the entity
No
Part 7B - Issue details
Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class
Will the proposed issue of this +security include an offer of attaching +securities?
No
Details of +securities proposed to be issued
ASX +security code and description
MSB : ORDINARY FULLY PAID
Number of +securities proposed to be issued
212,244
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
No
Please describe the consideration being provided for the +securities
The shares will be issued as consideration for services in connection with the license of intellectual property relating to cell targeting technology (ex vivo fucosylation) from a third party, for an equivalent consideration of US$240,000.
Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
340,000.000000
Proposed issue of securities | 3 / 5 |
Proposed issue of securities
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
Part 7C - Timetable
7C.1 Proposed +issue date
Thursday August 6, 2020
Part 7D - Listing Rule requirements
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?
Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?
212,244
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? Yes
7D.4a Please enter the number and +class of the +securities subject to +voluntary escrow and the date from which they will cease to be subject to +voluntary escrow
212,244 ordinary shares which will cease to be subject to voluntary escrow in 12 months
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue? No
Proposed issue of securities | 4 / 5 |
Proposed issue of securities
7E.2 Is the proposed issue to be underwritten? No
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue
Part 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
Consideration for services in connection with the license of intellectual property relating to cell targeting technology (ex vivo fucosylation) from a third party.
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No
7F.2 Any other information the entity wishes to provide about the proposed issue
Proposed issue of securities | 5 / 5 |
Attachments
- Original document
- Permalink
Disclaimer
Mesoblast Limited published this content on 06 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 August 2020 09:03:28 UTC